USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
The company received one observation in the Form-483
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The company received 1 (One) observation in the Form-483
Dilip Shanghvi to continue as the Executive Chairman of the Board
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Subscribe To Our Newsletter & Stay Updated